OTCM
ALRTF
, Last price
USD
Name
ALR Technologies Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ALR Technologies Inc. is a data management company dedicated to creating and providing diabetes care solutions for both human and animal health sectors across the United States. Central to its offerings is the comprehensive Diabetes Management System. This system facilitates data collection, provides predictive A1C analysis, offers recommendations for insulin dosage adjustments, tracks performance, enables remote patient monitoring, and supplies essential diabetes testing materials. The company also markets Continuous Glucose Monitoring (CGM) devices, which are wearable medical technologies designed to provide continuous blood sugar readings. Addressing a specific need in veterinary medicine, ALR Technologies offers the GluCurve Pet CGM, tailored for diabetic felines and canines, and utilized by veterinarians. Furthermore, their Prediabetes System supports patients with educational video content, supplementary resources optimized for mobile devices, and a private online community for discussing disease management strategies. ALR Technologies primarily serves healthcare providers, health insurance companies, and entities specializing in disease and case management services, including those within the home care industry. Originally incorporated in 1987 as Mo Betta Corp., the company rebranded to ALR Technologies Inc. in December 1998. It is based in Richmond, Virginia, and operates as a subsidiary of ALR Technologies SG Ltd.
Key people
Sidney S. Chan
Chairman of the Board of Directors, Chief Executive Officer, Chief Financial Officer · since 2011
Kenneth James Robulak
Independent Director · since 2012
Alfonso M. Salas
Independent Director · since 2012
Legal address
C/O Nevada Corporate Headquarters, Inc
4730 South Fort Apache Road
Suite 300
Las Vegas, NV 89147
US
4730 South Fort Apache Road
Suite 300
Las Vegas, NV 89147
US
Headquarters
7400 Beaufont Springs Drive
Suite 300
Richmond, VA 23225
US
Suite 300
Richmond, VA 23225
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||